When Matt Wilsey’s daughter Grace was diagnosed with NGLY1 deficiency—affecting fewer than 100 people globally—the family faced an unexpected barrier: the absence of any active research program. Rather than await traditional pharmaceutical timelines spanning 10-15 years, the Wilsey family established their own research initiative, fundamentally reshaping how regulatory agencies approach ultra-rare genetic disorders. Their patient-led model has compressed development timelines to 4-6 years while demonstrating how compassionate use pathways and regulatory flexibility can accelerate access to experimental gene therapies. This groundbreaking approach is influencing FDA policy, creating new precedents for conditions affecting only handfuls of patients worldwide. The case illustrates both the transformative potential of patient advocacy and the critical role independent research foundations now play in filling gaps left by traditional pharmaceutical development. Read the full article on GMJ Newsroom.
Was this article helpful?
